Abiopharma

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

New Form SCHEDULE 13G - Quoin Pharmaceuticals, Ltd. Filed: 2025-12-15 AccNo: 0001193125-25-319730 Size: 133 KB

Director RAKIN KEVIN 🔴 sold 4.4M shares of ELUTIA INC. (ELUT) Transaction Date: Dec 11, 2025 | Filing ID: 121336

Ramaswamy Vivek 🟡 adjusted position in 7.4M shares (3 derivative) of Roivant Sciences Ltd. (ROIV) at $22.05 ($348.5M) Transaction Date: Dec 11, 2025 | Filing ID: 000006

Director Duhay Francis 🟢 acquired 135.9K shares (1 derivative) of enVVeno Medical Corp (NVNO) at $0.33 Transaction Date: Dec 11, 2025 | Filing ID: 027848

Director Pershing Edward 🟢 acquired 15.7K shares (1 derivative) of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) at $2.86 Transaction Date: Dec 11, 2025 | Filing ID: 027846

New Form SCHEDULE 13D/A - TRINITY BIOTECH PLC Filed: 2025-12-15 AccNo: 0001193125-25-319692 Size: 275 KB

Director Gray Robert 🟢 acquired 135.9K shares (1 derivative) of enVVeno Medical Corp (NVNO) at $0.33 Transaction Date: Dec 11, 2025 | Filing ID: 027834

Director Jenusaitis Matthew 🟢 acquired 135.9K shares (1 derivative) of enVVeno Medical Corp (NVNO) at $0.33 Transaction Date: Dec 11, 2025 | Filing ID: 027832

📋 Erasca Foundation (Foundation) plans to sell 8K shares of Erasc, Inc. (at $3.65 each, total $30K) Filed: Dec 15, 2025 | ID: 057210